Pd-1 and pdl1 inhibitors immune checkpoint inhibitors market to reach $103.27 billion by 2030 at 14.6% cagr, driven by rising prevalence of cancer cases.
Read More
The non-radiographic axial spondyloarthritis therapeutic market is projected to reach $1.72 billion by 2030, growing at 10.6% CAGR, driven by biologics, JAK inhibitors, and early intervention.
Read More
Pcsk9 inhibitor market to reach $8.28 billion by 2030 at 20.6% cagr, driven by increasing hyperlipidemia prevalence.
Read More
Global Non-Proliferative Diabetic Retinopathy market size is expected to reach $3.96.8 billion by 2030 at 6.8%, segmented as by anti-vascular endothelial growth factor (vegf) therapy, bevacizumab (avastin), ranibizumab (lucentis), aflibercept (eylea)
Read More
The global parenteral nutrition market to reach $9.49 billion by 2030 at 6.0% cagr, driven by increasing birth rate.
Read More
Global Non-Muscle Invasive Bladder Cancer market size is expected to reach $4.82 billion by 2030 at 5.6%, the growing demand for minimally invasive procedures driving the market
Read More
The global parathyroid hormone market to reach $4.4 billion by 2030 at 11.9% cagr, driven by increasing geriatric population.
Read More
Parathyroid disease treatment market to reach $3.31 billion by 2030 at 6.8% cagr, driven by rising prevalence of chronic kidney disease.
Read More
Global Non-invasive Prenatal Testing market size is expected to reach $12.37 billion by 2030 at 14.4%, elevated down syndrome incidence and maternal age is fueling growth in non-invasive prenatal testing market
Read More
Pancreatic cancer precision medicine market to reach $1.24 billion by 2030 at 16.6% cagr, driven by rising prevalence of pancreatic cancer.
Read More